Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference
NC Companies Shine At SEBIO Forum
Humacyte Commences Phase II Vascular Trauma Trial
Humacyte Appoints Doug Blankenship as Chief Financial Officer
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.